21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 31.05.2026 Expectation: 11000 pips
USDCAD selloff starts from 1.4060
Yesterday at 11:43 AM 16
Period: 10.02.2026 Expectation: 9000 pips
Selling BTCUSD on rebound to $84,000 amid negative fundamentals
Yesterday at 11:06 AM 21
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 13.02.2026 Expectation: 2500 pips
Tesla stock slides toward $400
Yesterday at 08:37 AM 21
Period: 10.02.2026 Expectation: 1570 pips
Investing in AUDUSD on RBA hawkish policy shift
Yesterday at 07:04 AM 33
Period: 09.02.2026 Expectation: 815 pips
SPX is at risk of further correction due to revised rate expectations
02 February 2026 41
Period: 09.02.2026 Expectation: 1800 pips
Silver seeks firmer ground after historic plunge
02 February 2026 68
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Go to forecasts